Johnson & Johnson Urged To Expand Access To Tuberculosis Medication
Portfolio Pulse from Vandana Singh
Global health aid agency Unitaid is urging Johnson & Johnson (JNJ) to expand access to its tuberculosis (TB) drug, bedaquiline, particularly in countries with high TB cases. Unitaid has called on JNJ's CEO to remove all secondary patents, allowing for the production of generic versions of the drug. JNJ has confirmed its commitment not to enforce patents for bedaquiline in 134 designated low- and middle-income countries.
October 02, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Johnson & Johnson's commitment to not enforce patents for bedaquiline in certain countries could potentially lead to increased access to the drug, but also increased competition from generic versions. This could have mixed effects on the company's revenues.
While the increased access to bedaquiline could potentially boost sales volumes, the allowance for generic versions could introduce competition that may lower the drug's price, potentially impacting JNJ's revenues. The overall impact on the stock price is uncertain, hence the neutral score.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100